loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Vimta Labs Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Vimta Labs Ltd. 03 Nov 2025 14:54 PM
Result PDF

Q2FY26 Quarterly Result Announced for Vimta Labs Ltd.

Healthcare Services company Vimta Labs announced Q2FY26 results

Q2FY26 Financial Highlights:

  • Total Income for Q2FY26 was at Rs 1,045 million
  • EBITDA for Q2FY26 was Rs 369 million; EBITDA margin was at 35.3%
  • PBT for Q2FY26 was at Rs 263 million
  • Q2FY26 PAT was at Rs 199 million; PAT margin was at 19.1%
  • Basic EPS in Q2FY26 was Rs 4.5

H1FY26 Financial Highlights:

  • Total Income for H1FY26 was at Rs 2,038 million
  • EBITDA for H1FY26 was Rs 723 million; EBITDA margin was at 35.5%
  • PBT for H1FY26 was at Rs 515 million
  • H1FY26 PAT was at Rs 388 million; PAT margin was at 19.0%
  • Basic EPS in H1FY26 was Rs 8.7

Harita Vasireddi, Managing Director, Vimta Labs, said: "I am delighted to share that Vimta Labs had a successful quarter with highest ever revenue reported i.e. ~Rs 104 crore. This growth was a result of our Pharmaceutical research and testing services and Food testing services performing well, while experiencing stable performance from other services provided by us.

We would like to mention that our company had a successful WHO audit for Clinical Research during the quarter, reflecting our commitment to maintain the highest global standards of quality and compliance.

With a focus on maintaining excellence in quality, innovation, and competence, we continue to strengthen our capabilities and deliver sustainable value to all stakeholders.”

Result PDF

Result PDF

Healthcare Services company Vimta Labs announced Q1FY26 results

  • Total Income for Q1FY26 was at Rs 993 million.
  • EBITDA for Q1FY26 was Rs 354 million; EBITDA margin was at 35.7%.
  • PBT for Q1FY26 was at Rs 253 million.
  • Q1FY26 PAT was at Rs 189 million; PAT margin was at 19.0%
  • Basic EPS in Q1FY26 was Rs 4.2

Harita Vasireddi, Managing Director, Vimta Labs , said: “We are happy to report a revenue of Rs 993 million for the quarter which was driven by pharmaceutical & food contract research and testing services that we provide. I am pleased with the consistent progress Vimta continues to make in strengthening its service portfolio and deepening customer relationships across sectors.

Vimta completes a successful USFDA GCP inspection with zero Form 483 observations and received letter of cGMP compliance from ANSM (EMA) during the quarter. These outcomes are a reflection of Vimta's strong commitment to quality, and scientific rigor.

As a part of our efforts to enhance shareholder value, the Board has approved a Bonus issue in the ratio of 1:1, showcasing the company's strong financial position, confidence in future growth, and commitment to rewarding its shareholders.

Our focus remains on expanding our market reach and capabilities, fostering innovation, and creating sustainable long-term value for all our stakeholders.”

Result PDF

Healthcare Services company Vimta Labs announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Total Income for Q4FY25 was at Rs 961 million.
  • EBITDA for Q4FY25 was Rs 347 million; EBITDA margin was at 36.1%.
  • PBT for Q4FY25 was at Rs 250 million.
  • Q4FY25 PAT* was at Rs 183 million; PAT margin was at 19.1%.
  • Basic EPS in Q4FY25 was Rs 8.2.

FY25 Financial Highlights:

  • Total Income for FY25 was at Rs 3,482 million.
  • EBITDA for FY25 was Rs 1,262 million; EBITDA margin was at 36.2%.
  • PBT for FY25 was at Rs 890 million.
  • FY25 PAT* was at Rs 668 million; PAT margin was at 19.2%.
  • Basic EPS in FY25 was Rs 30.
  • Total Debt as of 31 st March 2025 stood at Rs 85 million.
  • Cash and Cash equivalents including bank balance stood at Rs 329 million as of 31 st March 2025.

Harita Vasireddi, Managing Director, Vimta Labs, said: "We are pleased to report strong earnings and good growth this year, driven by growth in pharmaceutical services. Our pharma business benefited from increased traction in clinical and analytical services, supported by capacity expansion and deeper client engagements.

Our continued investments in talent, infrastructure, and business development are strengthening our platform for long-term value creation.

We are excited to announce our entry into Biologics Contract R&D services, a strategic move that aligns with the future of healthcare and enhances our capabilities across the biopharma value chain. This initiative will enable Vimta to offer end-to-end support for biologics development, reinforcing our position as a trusted partner in high-quality, science-driven innovation.

We remain committed to scaling our capabilities, driving innovation, and delivering long-term value for our stakeholders.”

Result PDF

Healthcare Services company Vimta Labs announced 9MFY25 & Q3FY25 results

Q3FY25 Financial Highlights:

  • Total Income for Q3FY25 was at Rs 911 million.
  • EBITDA for Q3FY25 was Rs 343 million; EBITDA margin was at 37.6%.
  • PBT for Q3FY25 was at Rs 239 million.
  • Q3FY25 PAT was at Rs 175 million; PAT margin was at 19.2%.
  • Basic EPS in Q3FY25 was Rs 7.9.

9MFY25 Financial Highlights:

  • Total Income for 9MFY25 was at Rs 2,521 million.
  • EBITDA for 9MFY25 was Rs 915 million; EBITDA margin was at 36.3%.
  • PBT for 9MFY25 was at Rs 640 million.
  • 9MFY25 PAT was at Rs 484 million; PAT margin was at 19.2%.
  • Basic EPS in 9MFY25 was Rs 21.8.
  • Total Debt as of 31st December 2024 stood at Rs 113 million.
  • Cash and Cash equivalents including bank balance stood at Rs 180 million as of 31st December 2024.

Harita Vasireddi, Managing Director, Vimta Labs, said: "We are happy to report that Vimta Labs had another successful quarter with a strong growth of 21.1% YoY. This was mainly pushed by the Drug Development & Discovery Services. EBITDA margin for the quarter stood at 37.6% which is a growth of 496 bps on a YoY basis.

During the quarter, our new addition to the Life Sciences Facility, was commercialised which has helped ease our operations giving us the space to work more efficiently.

As we look to the future, we remain optimistic about our strategic direction and the robustness of our service offerings, which we believe will drive sustained growth and success.”

Result PDF

Healthcare Services company Vimta Labs announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • Total Income for Q2FY25 was at Rs 854 million.
  • EBITDA for Q2FY25 was Rs 306 million; EBITDA margin was at 35.8%.
  • PBT for Q2FY25 was at Rs 219 million.
  • Q2FY25 PAT was at Rs 170 million; PAT margin was at 19.9%.
  • Basic EPS in Q2FY25 was Rs 7.7.

H1FY25 Financial Highlights:

  • Total Income for H1FY25 was at Rs 1,610 million.
  • EBITDA for H1FY25 was Rs 572 million; EBITDA margin was at 35.5%.
  • PBT for H1FY25 was at Rs 401 million.
  • H1FY25 PAT was at Rs 309 million; PAT margin was at 19.2%.
  • Basic EPS in H1FY25 was Rs 13.9.
  • Total Debt as of 30th September 2024 stood at Rs 116 million.
  • Cash and Cash equivalents including bank balance stood at Rs 278 million as of 30th September 2024.

Harita Vasireddi, Managing Director, Vimta Labs, said: "We are pleased to report a strong operational performance for Q2FY25, with revenues of Rs 854 million, reflecting a 26.4% YoY growth. Our EBITDA rose by 57.3% YoY, and net profit surged by 109.9%. This performance was primarily driven by our pharmaceutical services, which continue to lead the business.

As stated in our August 30, 2024, press release, Vimta Labs has divested the Diagnostic and Pathological services business to Thyrocare Technologies. This decision allows us to sharpen our focus on core services and optimize resources for sustained growth, resulting in a significant improvement in our EBITDA margins, which now exceed 35%, up from the previous range of 23% to 30%.

Looking ahead, our Pharmaceutical services continue to show promising growth, and we anticipate that our food testing services will also contribute to growth in coming quarteRs We are also expanding our electrical and electronics testing capabilities and preparing to commission a new facility in couple of quarteRs We remain committed to driving sustainable and impactful growth for our investors.”

Result PDF

Healthcare Services company Vimta Labs announced Q1FY25 results:

  • Total Income for Q1FY25 was at Rs 824 million
  • EBITDA for Q1FY25 was Rs 252 million; EBITDA margin was at 30.6%
  • PBT for Q1FY25 was at Rs 165 million
  • Q1FY25 PAT was at Rs 123 million; PAT margin was at 14.9%
  • Basic EPS in Q1FY25 was Rs 5.5
  • Total Debt as of June 30, 2024 stood at Rs 130 million
  • Cash and Cash equivalents were at Rs 324 million as of June 30, 2024
  • Q1FY25 Capex spent was at Rs 164 million
  • Debt to Equity ratio was 0.04x

Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs, said: "We are pleased to report stable business momentum with encouraging QoQ sales growth and stable EBITDA margins. Despite a challenging internal and external environment, we achieved a QoQ growth in sales, driven by Pharmaceutical services which demonstrated sustained growth, albeit slightly tempered by the other services.

Looking ahead, we are pleased to share that our new Life Sciences facility expansion will become operational in Q2 of this financial year. This facility is expected to play a significant role in driving our growth in the coming quarters. We remain optimistic about the future and are dedicated to fostering sustainable growth."

Result PDF

Healthcare Services company Vimta Labs announced consolidated Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Total Income for Q4FY24 was at Rs 802 million
  • EBITDA for Q4FY24 was Rs 249 million; EBITDA margin was at 31.1%
  • Q4FY24 PAT was at Rs 124 million
  • Basic EPS in Q4FY24 was Rs 5.6

FY24 Financial Highlights:

  • Total Income for FY24 was at Rs 3,223 million
  • EBITDA for FY24 was Rs 908 million; EBITDA margins at 28.2%
  • FY24 PAT was at Rs 410 million
  • Basic EPS was Rs 18.5 in FY24
  • Cash flow From Operations at Rs 609 million for FY24; FY24 Capex at Rs 763 million
  • Cash and Cash equivalents at Rs 258 million as of 31st March 2024
  • Debt to Equity ratio 0.06x

Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs Limited, said: “Q4 maintained good recovery after H1 being harsh on us. Having a strong and resilient business model has helped us strive through some headwinds and get back to the historical figures.

Our services to the Pharmaceutical industry have seen a promising uptick, demonstrating growth in both pre-clinical and analytical services. We have recently expanded our offerings to include clinical trials, which we anticipate will be a major driver of future growth.

The Food segment experienced initial setbacks due to supply chain disruptions caused by various external factors. However, this segment has begun to recover and shows promise for continued improvement. Our new Electronics and Electrical testing division delivered strong results, while our other segments have gone through some corrections in services and their scale.

Looking forward, we are confident in our ability to achieve significant growth. While FY24 presented unforeseen challenges, we are optimistic that FY25 will be a year of robust expansion for the company.”

Result PDF

Healthcare Services company Vimta Labs announced Q2FY24 & H1FY24 results:

  • Total Income for Q2FY24 was at Rs 754 million a de-growth of 6.4% YoY
  • EBITDA for Q2FY24 was Rs 179 million a decline of 31.4% YoY; EBITDA margin was at 23.8%
  • Total Income for H1FY24 was at Rs 1,595 million a de-growth of 0.7% YoY
  • EBITDA for H1FY24 was Rs 432 million a decline of 15.3% YoY; EBITDA margins at 27.1%
  • Cash and Cash equivalents at Rs 262 million as of September 30, 2023
  • Cash flow From Operations at Rs 268 million for H1FY24; H1FY24 Capex at Rs 421 million
  • Debt to Equity ratio 0.07

Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs, said, “The downtrend in our income has primarily stemmed from the Pharma and Food business, which saw decreased demand and lower volumes respectively. Conversely, our E&E business continues to perform well, with Environment and Diagnostics remained stable.

Given the headwinds from the broader economic uncertainties, we acknowledge the external challenges. However, our ongoing dialogues with clients along with the stability provided by our long-term contracts and revenue visibility for the H2FY24 keeps me optimistic of delivering growth in FY24.”

 

Result PDF

Healthcare Services company Vimta Labs announced Q1FY24 results:

  • Total Income for Q1FY24 was at Rs 841 million
  • EBITDA for Q1FY24 was Rs 252 million; EBITDA margin remained steady at 30.0%
  • Q1FY24 PAT was at Rs 122 million; PAT Margins for the quarter was at 14.5%
  • Basic EPS was at Rs 5.5 in Q1FY24 as against Rs 5.4 in Q1FY23
  • Total Debt as of 30th June 2023 stood at Rs 137 million down from Rs 150 million as of 31st March 2023
  • Cash and Cash equivalents were at Rs 285 million as of 30th June 2023
  • Q1FY24 Capex was at Rs 218 million
  • Debt to Equity ratio was 0.05x

Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs, said: “We are extremely pleased with the continued growth momentum despite a challenging external environment. During Q1FY24, our total income was Rs 841 million. The Pharma segment led the growth during the quarter with the food segment getting impacted due to the Biparjoy cyclone whereas other segments remained stable.

While the external environment remains uncertain, robust demand in the TIC market gives us the confidence of delivering strong growth in the coming quarters”

 

 

Result PDF

Trending News

ACE and Sanghvi Movers have signed a strategic MoU

ACE and Sanghvi Movers have signed a strategic MoU

Published on 12-Dec-2025 09:05

Chalet Hotels has announced its plans to acquire a resort in Udaipur

 Chalet Hotels has announced its plans to acquire a resort in Udaipur

Published on 12-Dec-2025 09:04

Union Cabinet is expected to consider the Insurance Amendment Bill that proposes major regulatory changes

Union Cabinet is expected to consider the Insurance Amendment Bill that proposes major regulatory changes

Published on 12-Dec-2025 09:01

Mexico government has announced raising import tariffs on vehicles, two-wheelers, and auto parts

Mexico government has announced raising import tariffs on vehicles, two-wheelers, and auto parts

Published on 12-Dec-2025 09:00

Cipla launches Yurpeak (tirzepatide) therapy.

Cipla has announced the launch of Yurpeak (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes. 

Published on 11-Dec-2025 09:06

US Fed cuts interest rate range

US Federal Reserve cut interest rate to a range between 3.5% and 3.75%, the lowest level in almost 3-years at its 3rd consecutive meeting but signaled borrowing costs are unlikely to drop further in the near term. 

Published on 11-Dec-2025 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status